Functional coupling of angiotensin II type 1 receptor with insulin resistance of energy substrate uptakes in immortalized cardiomyocytes (HL-1 cells)

British Journal of Pharmacology

Volumn 153, Issue 5, 2008, Pages 907-914

  Alfarano, C ^a   Sartiani, L ^a   Nediani, C ^a   Mannucci, E ^a   Mugelli, A ^a   Cerbai, E ^a   Raimondi, L ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Angiotensin II type 1 receptor blockers; Fatty acid uptake; Glucose uptake; HL 1 cells; Hypertrophy; Insulin resistance

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 DEOXYGLUCOSE H 3; ANGIOTENSIN 1 RECEPTOR; CARBON 14; GLUCOSE; IRBESARTAN; LEUCINE H 3; PALMITIC ACID C 14; THYMIDINE H 3; TRITIUM; UNCLASSIFIED DRUG;

ARTICLE; CELL IMMORTALIZATION; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFECT; HEART MUSCLE CELL; HUMAN; HUMAN CELL; HYPERTROPHY; INSULIN RESISTANCE; PRIORITY JOURNAL; WESTERN BLOTTING;

EID: 40149108051     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0707563     Document Type: Article

References (28)

1. Bani D, Giannini L, Ciampa A, Masini E, Suzuki Y, Menegazzi M et al. (2006). Epigallocatechin‐3‐gallate reduces allergen‐induced asthma‐like reaction in sensitized guinea pigs. J Pharmacol Exp Ther 317: 1002–1011.
2. Bonen A, Luiken JJ, Glatz JF (2002). Regulation of fatty acid transport and membrane transporters in health and disease. Mol Cell Biochem 239: 181–192.
3. Chabowski A, Coort SL, Calles‐Escandon J, Tandon NN, Glatz JF, Luiken JJ et al. (2005). The subcellular compartmentation of fatty acid transporters is regulated differently by insulin and by AICAR. FEBS Lett 579: 2428–2432.
4. Chaudary N, Shuralyova I, Liron T, Sweeney G, Coe IR (2002). Transport characteristics of HL‐1 cells: a new model for the study of adenosine physiology in cardiomyocytes. Biochem Cell Biol 80: 655–665.
5. Chen V, Ianuzzo CD, Fong BC, Spitzer JJ (1984). The effects of acute and chronic diabetes on myocardial metabolism in rats. Diabetes 33: 1078–1084.
6. Clarke TC, Thomas D, Petersen JS, Evans WH, Martin PEM (2006). The antiarrhythmic peptide rotigaptide (ZP123) increases gap junction intercellular communication in cardiac myocytes and HeLa cells expressing connexin. Br J Pharmacol 147: 486–495.
7. Coort SL, Luiken JJ, Van der Vusse GJ, Bonen A, Glatz JF (2004). Increased FAT (fatty acid translocase)/CD36‐mediated long‐chain fatty acid uptake in cardiac myocytes from obese Zucker rats. Biochem Soc Trans 32: 83–85.
8. Fang ZY, Prins JB, Marwick TH (2004). Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications. Endocr Rev 25: 543–567.
9. Filipeanu CM, Zhou F, Claycomb WC, Wu G (2004). Regulation of the cell surface expression and function of angiotensin II type 1 receptor by Rab1‐mediated endoplasmic. J Biol Chem 279: 41077–41084.
10. Fischer Y, Thomas J, Sevilla L, Munoz P, Becker C, Holman G et al. (1997). Insulin‐induced recruitment of glucose transporter 4 (GLUT4) and GLUT1 in isolated rat cardiac myocytes. Evidence of the existence of different intracellular GLUT4 vesicle populations. J Biol Chem 272: 7085–7092.
11. Fukuda K, Davies SS, Nakajima T, Ong BH, Kupershmidt S, Fessel J et al. (2005). Oxidative mediated lipid peroxidation recapitulates proarrhythmic effects on cardiac sodium channels. Circ Res 97: 1262–1269.
12. Izawa Y, Yoshizumi M, Fujita Y, Ali N, Kanematsu Y, Ishizawa K et al. (2005). ERK1/2 activation by angiotensin II inhibits insulin‐induced glucose uptake in vascular smooth muscle cells. Exp Cell Res 308: 291–299.
13. Juan CC, Chien Y, Wu LY, Yang WM, Chang CL, Lai YH et al. (2005). Angiotensin II enhances insulin sensitivity in vitro and in vivo. Endocrinology 146: 2246–2254.
14. Lerch M, Teuscher AU, Beissner P, Schneider M, Shaw SG, Weidmann P (1998). Effects of angiotensin II‐receptor blockade with losartan on insulin sensitivity, lipid profile, and endothelin in normotensive offspring of hypertensive parents. J Cardiovasc Pharmacol 31: 576–580.
15. Luiken JJ, Bonen A, Glatz JF (2002a). Cellular fatty acid uptake is acutely regulated by membrane‐associated fatty acid‐binding proteins. Prostaglandins Leukot Essent Fatty Acids 67: 73–78.
16. Luiken JJ, Coort SL, Koonen DP, van der Horst DJ, Bonen A, Zorzano A et al. (2004). Regulation of cardiac long‐chain fatty acid and glucose uptake by translocation of substrate transporters. Pflugers Arch 448: 1–15.
17. Luiken JJ, Koonen DP, Willems J, Zorzano A, Becker C, Fischer Y et al. (2002b). Insulin stimulates long‐chain fatty acid utilization by rat cardiac myocytes through cellular redistribution of FAT/CD36. Diabetes 51: 3113–3119.
18. Montessuit C, Thorburn A (1999). Transcriptional activation of the glucose transporter GLUT1 in ventricular cardiac myocytes by hypertrophic agonists. J Biol Chem 274: 9006–9012.
19. Mosmann T (1983). Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55–63.
20. Opie LH (2004). The metabolic vicious cycle in heart failure. Lancet 364: 1733–1734.
21. Palanivel R, Eguchi M, Shuralyova I, Coe I, Sweeney G (2006). Distinct effects of short‐ and long‐term leptin treatment on glucose and fatty acid uptake and metabolism in HL‐1 cardiomyocytes. Metabolism 55: 1067–1075.
22. Raimondi L, De Paoli P, Mannucci E, Lonardo G, Sartiani L, Banchelli G et al. (2004). Restoration of cardiomyocyte functional properties by angiotensin II receptor blockade in diabetic rats. Diabetes 53: 1927–1933.
23. Rajapurohitam V, Javadov S, Purdham DM, Kirshenbaum LA, Karmazyn M (2006). An autocrine role for leptin in mediating the cardiomyocyte hypertrophic effects of angiotensin II and endothelin‐1. J Mol Cell Cardiol 41: 265–274.
24. Sartiani L, Bochet P, Cerbai E, Mugelli A, Fishmeister R (2002). Functional expression of the hyperpolarization‐activated, non selective cation current I(f) in immortalized HL‐1 cardiomyocytes. J Physiol 545: 81–92.
25. Schmieder RE (2005). Optimizing therapeutic strategies to achieve renal and cardiovascular risk reduction in diabetic patients with angiotensin receptor blockers. J Hypertens 23: 905–911.
26. Stanley WC (2005). Ranolazine: new approach for the treatment of stable angina pectoris. Expert Rev Cardiovasc Ther 3: 821–829.
27. Stanley WC, Lopaschuk GD, McCormack JG (1997). Regulation of energy substrate metabolism in the diabetic heart. Cardiovasc Res 34: 25–33.
28. White SM, Costantin PE, Claycomb WC (2004). Cardiac physiology at the cellular level: use of cultured HL‐1 cardiomyocytes for studies of cardiac muscle structure and function. Am J Physiol Heart Circ Physiol 286: H823–H829.